This roundtable series examines options for patients with KRAS G12C-mutated non–small cell lung cancer, as discussed by key opinion leaders and participants at virtual live events.
Konduri Discusses Data Behind Treatment of KRAS G12C–Harboring NSCLC
In the first of a 2-part article series, Kartik Konduri, MD, discusses the data behind the use of adagrasib and sotorasib for patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation.
Data Provides Insight for Using KRAS Inhibition in NSCLC
In the second part of a 2-part article series, Kartik Konduri, MD, discusses the outcomes of targeting the KRAS G12C mutation in patients with metastatic NSCLC.
2 Clarke Drive Cranbury, NJ 08512